I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Kor...
I-Mab Announces Upcoming Participation at October Conferences
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021The current U.S. NHL clinical trial has now expanded to include clinical sites inChina as an international multi-center clinical trial, which will potentially lead to a r...
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China Nati...
I-Mab Added to FTSE ESG Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Env...
I-Mab Added to FTSE Russell Global Equity Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...
I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...
I-Mab Announces Establishment of Environmental, Social and Governance Committee
* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021
SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and repo...
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
SHANGHAI and GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors (the "Board") has authorized...
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
SHANGHAI and GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that onJuly 27, 2021, the Board of Directors of the Comp...
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
I-Mab Honored with Top Rankings by Institutional Investor
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading gl...
I-Mab Announces Upcoming Participation at July Conference
SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment ofAndrew Zhu, MD, PhD, to the Company's ...
